NIKKEI 225
38,837.46 -85.54 (-0.22%) HANG SENG
18,444.11 +41.11 (+0.22%) CRUDE OIL
73.28 -0.94 (-1.27%) GOLD FUTURES
2,344.60 -24.70 (-1.04%) DOW
38,569.05 -1.98 (-0.01%) Bitcoin GBP
55,366.93 +1,360.17 (+2.52%)
REGN Jun 2024 570.000 call
| Previous close | 247.00 |
| Open | N/A |
| Bid | 246.00 |
| Ask | 254.00 |
| Strike | 570.00 |
| Expiry date | 2024-06-21 |
| Day's range | 247.00 - 247.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
Insider MonkeyIs Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) the Best Bet in Gene Therapy Industry?
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is the best bet in the gene therapy sector. Gene therapy involves treating illnesses by modifying, replacing, or supplementing faulty or missing genes responsible for a disease. This approach […]
BenzingaFDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
On Friday, the FDA extended the target action date of priority review of supplemental application seeking approval for Dupixent (dupilumab) as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD), a lung disease that’s usually caused by smoking. The revised target action date is September 27, 2024. The FDA accepted the application in February, with a target action date of June 27, 2024. The FDA did not raise any concerns regardi
ZacksFDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
Per the FDA, the data submitted by Sanofi (SNY)/Regeneron (REGN) for Dupixent in COPD indication constitutes a major amendment to its previously-submitted data. A final decision is expected by Sep 27.
